Skip to main content
. 2023 Aug 23;24(17):13077. doi: 10.3390/ijms241713077

Figure 2.

Figure 2

Summary of treatment for case 1. MET alterations in red. LAC: lung adenocarcinoma; PS: performance status; PY: pack-years; cfDNA: cell-free DNA; Osi: Osimertinib; Crizo: Crizotinib.